1. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G: Pharmaceutical co-crystals: An overview. Int J Pharm. 2011, 419: 1-11. 10.1016/j.ijpharm.2011.07.037.
2. Peterson ML, Collier EA, Hickey MB, Guzman H, Almarsson O: Multi-component pharmaceutical crystalline phases. Engineering for performance. Edited by: Tiekink ERT, Vittal J, Zaworotko M. 2010, Organic crystal engineering: Frontiers in Crystal Engineering, John Wiley & Sons, Ltd, Chichester, UK, Chapter 3
3. Aitipamula S, Chow PS, Tan RBH: Trimorphs of a pharmaceutical co-crystal involving two active pharmaceutical ingredients: potential relevance to combination drugs. Cryst Eng Comm. 2009, 11: 1823-1827. 10.1039/b904616j.
4. Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ: Coformer selection in pharmaceutical co-crystal development: A case study of a meloxicam aspirin co-crystal that exhibits enhanced solubility and pharmacokinetics. J. Pharm Sci. 2011, 100: 2172-2181. 10.1002/jps.22434.
5. Brittain HG, Felice PV: Intravenous formulation with water-soluble co-crystals of acetylsalicylic acid and theanine. 2010, United States Patent Application US/2010-0286099